Oncology Institute (TOI) recently drew fresh investor attention after announcing that Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet, joined its Board of Directors, bringing additional healthcare and public markets experience.

The board appointment comes as Oncology Institute’s share price has gained momentum, with a 21.1% 7 day share price return and a strong 1 year total shareholder return, although the 5 year total shareholder return remains negative.

If this kind of healthcare story has your attention, it could be a good moment to scan other healthcare stocks that might fit your watchlist next.

So with TOI shares up 21.1% in a week and trading at a discount to a US$6.50 analyst price target, is the market overlooking value here, or already factoring in all the future growth potential?

Most Popular Narrative: 38.4% Undervalued

With Oncology Institute’s last close at US$4.31 and a most popular fair value of US$7.00, the current price sits well below that narrative mark.

The company's recent contract wins and expansions, especially in Florida and Nevada, are rapidly increasing patient lives under value-based arrangements; as these new contracts mature and more patients transition into TOI's care model, revenue per patient and overall patient volumes are positioned for strong growth, supporting top-line expansion.

Curious what kind of revenue ramp, margin shift, and valuation multiple are baked into that story? The narrative leans heavily on growth forecasts and a specific profit profile. Want to see exactly how those assumptions stack up over time?

Result: Fair Value of $7.0 (UNDERVALUED)

However, that story can break if reimbursement terms tighten on Medicare Advantage and Medicaid, or if new capitated contracts take longer than expected to reach healthier margins.

Build Your Own Oncology Institute Narrative

If you see the numbers differently or prefer to test the assumptions yourself, you can build a custom thesis in just a few minutes with Do it your way.

A great starting point for your Oncology Institute research is our analysis highlighting 2 key rewards and 5 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If TOI has sparked your interest, do not stop here. Broaden your watchlist with a few focused screens that surface very different kinds of opportunities.

• Target potential mispricings by checking out these 881 undervalued stocks based on cash flows that may offer more for the price than the market currently reflects.
• Explore tech themes by scanning these 28 AI penny stocks that are tied to artificial intelligence growth stories across multiple industries.
• Strengthen your income focus by reviewing these 11 dividend stocks with yields > 3% that might suit a portfolio built around regular cash returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.